Literature DB >> 12163304

Follicular dendritic cells as targets for intervention in transmissible spongiform encephalopathies.

Neil A Mabbott1, Moira E Bruce.   

Abstract

Transmissible spongiform encephalopathies (TSEs) are often acquired peripherally, for example by ingestion or iatrogenic exposure. After entry, TSE agents, as identified by disease-specific protein accumulation, usually accumulate on follicular dendritic cells (FDCs) in lymphoid tissues long before infection spreads to the brain. Neuroinvasion of TSE agents is significantly impaired in the absence of mature FDCs. Treatments that interfere with the integrity or function of FDCs extend survival time by blocking replication in lymphoid tissues and spread to the brain. The identification of FDCs as critical for TSE pathogenesis provides a cellular target to which therapies can be specifically directed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163304     DOI: 10.1016/s1044-5323(02)00061-1

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  4 in total

Review 1.  How do follicular dendritic cells interact intimately with B cells in the germinal centre?

Authors:  Chan-Sik Park; Yong Sung Choi
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

2.  Enhancement of immunohistochemical staining of scrapie proteins and immune cells within lymph nodes of early scrapie-infected sheep.

Authors:  Annissa Furr; David Knudsen; Michael B Hildreth; Alan J Young
Journal:  J Immunol Methods       Date:  2011-06-23       Impact factor: 2.303

3.  Resistance of neonatal mice to scrapie is associated with inefficient infection of the immature spleen.

Authors:  Michelle Ierna; Christine F Farquhar; George W Outram; Moira E Bruce
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Follicular dendritic cell dedifferentiation reduces scrapie susceptibility following inoculation via the skin.

Authors:  Joanne Mohan; Moira E Bruce; Neil A Mabbott
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.